DGX Systematic Research
Quest Diagnostics demonstrates defensive characteristics within the diagnostic services sector, evidenced by a beta of 0.54 that positions the equity as considerably less volatile than broader market indices. Trading at $233.01 with a market capitalization of $25.7 billion, the company sits near the upper end of its 52-week range of $166.75–$240.13, reflecting sustained institutional interest in healthcare infrastructure assets.
Systematic screening highlights several fundamental strengths:
- Accelerating profitability metrics: The 13.01% year-over-year EPS growth outpaces revenue expansion of 9.87%, indicating operational leverage and margin improvement. Net margin of 9.19% translates to trailing twelve-month earnings per share of $9.44, supporting the current P/E ratio of 24.38.
- Stable balance sheet structure: The debt-to-equity ratio of 0.82 remains within manageable parameters for capital-intensive laboratory operations, while the current ratio of 1.04 suggests adequate short-term liquidity coverage.
- Consistent return generation: ROE of 14.49% exceeds the company's cost of equity for most modeling scenarios, with ROA of 6.43% reflecting asset-intensive business model characteristics typical of nationwide diagnostic networks.
The research perspective identifies valuation compression risk, as the P/B ratio of 2.69 represents premium pricing relative to book value of $65.18 per share. Regulatory reimbursement pressures present ongoing margin headwinds within clinical laboratory services. Against peers including Laboratory Corporation (LH), Cigna (CI), and CVS Health (CVS), DGX maintains differentiated exposure as a pure-play diagnostics provider with higher operating margins of 14.1%, offering portfolio diversification within healthcare services allocations.
Analysis updated monthly based on systematic screening of fundamentals, profitability, growth, and peer positioning.